|
| Press Releases |
|
 |
|
| Monday, May 31, 2021 |
|
|
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia |
| Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concerning the initiatives for supporting people living with and preventing dementia with the aim of realizing a healthy and long-lived society. more info >> |
|
| Wednesday, September 24, 2025 |
|
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers. more info >> |
|
| Wednesday, September 17, 2025 |
|
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). more info >> |
|
| Friday, September 12, 2025 |
|
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the release of a concept movie and new content on the dedicated website for its "New Answers to Dementia" campaign, designed to increase corporate awareness. more info >> |
|
| Monday, September 8, 2025 |
|
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. more info >> |
|
| Thursday, September 4, 2025 |
|
|
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2 receptor agonist (OX2R) E2086 and the latest findings on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO(R)) at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10. more info >> |
|
| Wednesday, September 3, 2025 |
|
|
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
| Monday, September 1, 2025 |
|
|
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIKTM, pronounced "I Click") for maintenance dosing. more info >> |
|
| Friday, August 29, 2025 |
|
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Monday, August 25, 2025 |
|
|
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
富士通 Japan、生成 AI を活用した医療文章作成支援サービスを名古屋医療センター様に導入し、退院サマリを対象に本格運用開始
Nov 19, 2025 11:10: JST
|
|
|
「躍動長城」中國長城動畫短片計劃正式啟動
Nov 19, 2025 09:41 HKT/SGT
|
|
|
OBI-902、米国FDAより胆管癌治療を対象とした希少疾病用医薬品指定を取得
Nov 19, 2025 09:00: JST
|
|
|
CM Energy's Green Methanol Breaks Into EU Market With ISCC EU Certification
Nov 19, 2025 08:00 HKT/SGT
|
|
|
GMG G-LUBRICANT Achieves 13.8% Fuel Saving in Major Australian Charity Rally
Nov 18, 2025 20:39 HKT/SGT
|
|
|
15th Asian Logistics, Maritime and Aviation Conference draws to successful conclusion
Nov 18, 2025 19:53: JST
|
|
|
15th Asian Logistics, Maritime and Aviation Conference draws to successful conclusion
Nov 18, 2025 18:53 HKT/SGT
|
|
|
Kincora Commences Drilling at the Wongarbon Porphyry Project
Nov 18, 2025 18:29 HKT/SGT
|
|
|
Kaspersky、AI駆動型ツールを駆使してWindowsとmacOSを使用する経営幹部を標的とするBlueNoroffの攻撃を発表
Nov 18, 2025 18:05: JST
|
|
|
DigiTech ASEAN Thailand & AI Connect 2025: The Gateway to Digital Transformation in Southeast Asia
Nov 18, 2025 18:00 HKT/SGT
|
|
|
「香港繪本出版支援計劃」率本地繪本插畫師 登上2025中國上海國際童書展
Nov 18, 2025 17:22 HKT/SGT
|
|
|
TuneFab音楽変換ツールVer4.0がリリース：さらなる高品質の音楽再生と管理体験を提供
Nov 18, 2025 16:00: JST
|
|
|
華商能源綠色甲醇斬獲歐盟市場准入證
Nov 18, 2025 15:43 HKT/SGT
|
|
|
华商能源绿色甲醇斩获欧盟市场准入证
Nov 18, 2025 15:24 HKT/SGT
|
|
|
Icarus' Future: A Miami-Born Campaign Telling COP30 Leaders Our Children's Future is at Stake - Just Won Seven LUUM Awards
Nov 18, 2025 08:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
